52w high/low | ₹370.45 / ₹99.5 |
P/E ratio | 39.55 |
Dividend | 1.32 |
ROE | 7.9 |
ROCE | 9.35 |
Face value | 10 |
Book value | ₹82.05Cr |
Market capital | ₹1,092.69Cr |
What is shareholding pattern? Who are shareholders?
What is a cash flow statement?
What is a balance sheet?
What is a profit and loss statement?
What are dividends?
What are bonuses?
Kopran was promoted by the Somani group and is controlled by Parijat Enterprises. The company came out with a public issue at a premium, in Nov. '92, to finance its backward integration project to produce drug intermediates for semi-synthetic drugs, and also to expand its antibiotic facility. Kopran manufactures pharmaceutical finished dosage forms and bulk drugs and distributes electronic equipment. It manufactures semi-synthetic penicillin and is among the world's highest producers in amoxycillin. Kopran also makes penicillin-G acylase, an enzyme made through fermentation. It has technical collaborations with Gesellschaft Fur Biotechnologische, Germany; Yuhan Corporation, South Korea; Ciba Corning Diagnostic, US; and Adac Laboratories, US. Kopran's bulk drug plant has been approved by the US FDA and the UK regulatory authorities.